Marta Casarrubios

Majadahonda, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: September 26, 2024

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Journal: Journal for immunotherapy of cancer

Published: September 13, 2022

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 16, 2022

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.

Journal: Journal for immunotherapy of cancer

Published: July 29, 2021

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Journal: Clinical and translational medicine

Published: April 13, 2021

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.

Journal: ESMO open

Published: April 06, 2021

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 31, 2021

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.

Journal: Biomedicines

Published: February 28, 2021

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: May 14, 2020

PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?

PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?

Journal: BMC cancer

Published: October 10, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026